Physician profile
Beau B Meyer
NPI 1922056720
$9,063.95
in general payments reported to CMS, 2019-2025
54 companies · $1,947 in 2025
The $1,947 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,960 · 2020: $454 · 2021: $227 · 2022: $1,542 · 2023: $1,491 · 2024: $1,443 · 2025: $1,947.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,881.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,880.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $847.55 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $784.69 | 2019-2025 | |
| Pfizer INC. | $748.23 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $713.66 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $671.45 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $630.50 | 2022-2025 | |
| Amgen INC. | $618.91 | 2019-2025 | Otezla, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $496.19 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $449.64 | 2020-2025 | Zepbound, Mounjaro, Jardiance |
| Merck Sharp & Dohme LLC | $314.43 | 2019-2025 | Capvaxive, Gardasil 9, Verquvo |
| Exact Sciences Corporation | $195.15 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Idorsia Pharmaceuticals US INC | $172.06 | 2022-2025 | Quviviq, Quviviq |
| Janssen Pharmaceuticals, INC | $167.19 | 2019-2025 | Spravato |
| Corcept Therapeutics | $163.64 | 2024-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $139.21 | 2019-2025 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beau Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.